£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

Physicians see value in consumer drug ads, but want more financial and adherence information, survey finds

Physicians don’t hate prescription drug ads, they just want the promotions to do more. That’s according to Syneos Health’s most recent AnswerSuite survey of healthcare

July 12, 2023

Researchers urge inclusion of marginalized groups to bridge bulimia nervosa treatment gaps

Researchers identified significant disparities in bulimia nervosa treatment, urging more inclusive research to address gaps in care for marginalized populations.

August 16, 2024

Viatris licenses Idorsia’s PhIII heart and lupus drugs with $350M upfront

Viatris has inked a deal with Idorsia for a pair of late-stage drug candidates in a move that may reflect Viatris’ efforts to build its

February 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.